Login Register Cart 0
Generic placeholder image

Current Nutrition & Food Science

Editor-in-Chief

ISSN (Print): 1573-4013
ISSN (Online): 2212-3881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective Article

Milk Oligosaccharides and Lectins as Candidates for Clinical Trials against Covid-19

Author(s): Mourad Errasfa*

Volume 17, Issue 3, 2021

Published on: 19 August, 2020

Page: [246 - 248] Pages: 3

DOI: 10.2174/1573401316999200819125355

Abstract

Background: Covid-19 pandemic is causing a very high death toll around the world and a severe fall in the global economy. Many clinical trials are currently underway to check the effectiveness of some known drugs. The physiopathology associated with the virus infection is currently better understood and good prophylactic drug therapies are implemented, such as antibiotics and blood thinners, though, no specific drugs against SARS-Cov-2 were developed yet.

Objective: In the present research work, it is aimed to carry out a bibliographic investigation on some active molecular species that could be used against Covid-19, based on their chemical properties to bind to glycoproteins. In the case of SARS-Cov-2, the targeted glycoprotein is the surface virus spike S glycoprotein, that the virus uses to attach to and invade human cells. It is of high pharmacological value to investigate possible active natural substances endowed with a property to bind glycoproteins. In this line of research, oligosaccharides and lectins are two molecular species that have glycoprotein binding properties.

Methods: A bibliographic research was carried out on oligosaccharides and lectins in various sources of scientific publications. Relevant chemical and pharmacological properties of oligosaccharides and lectins were searched and their main natural sources were identified.

Results: In the present paper, I summarize some scientific evidence to support the therapeutic potential of camel milk as a source of oligosaccharides and its possible use as a functional diet in parallel to drug therapies of Covid-19. On the other hand, sugar and glycoprotein binding properties of some lectins of plant and seaweed origin are reported, and their pharmaceutical use is underlined.

Conclusion: In the present study, scientific evidence was documented that encouraged further clinical investigations on camel milk oligosaccharides and lectins of plant and seaweed origin in the management of Covid-19 physiopathology.

Keywords: Covid-19, SARS-Cov2, milk oligosaccharides, lectins, clinical trial, antiviral.

« Previous Next »
Graphical Abstract

[1]
Wu F, Zhao S, Yu B, et al. Author Correction: A new coronavirus associated with human respiratory disease in China. Nature 2020; 580(7803): E7.
[http://dx.doi.org/10.1038/s41586-020-2202-3] [PMID: 32296181]
[2]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-92.e6.
[http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
[3]
Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta 2020; 507: 174-80.
[http://dx.doi.org/10.1016/j.cca.2020.04.024] [PMID: 32339487]
[4]
Covid-19 registered trials and analysis. Available at: https://www.cebm.net/covid-19/registered-trials-and-analysis/
[5]
Lancement d’un essai clinique européen contre le Covid-19. Available at: https://presse.inserm.fr/lancement-dun-essai-clinique-europeen-contre-le-covid-19/38737/
[6]
Landscape analysis of therapeutic 2020. Available at: https://www.who.int/blueprint/priority-diseases/key action/Table_of_therapeutics_Appendix_17022020.pdf
[7]
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421-4.
[http://dx.doi.org/10.1111/jth.14830] [PMID: 32271988]
[8]
Giannis D, Ziogas IA, Gianni P. Coagulation disorders in corona-virus infected patients: COVID-19, SARS-CoV-1, MERS- CoV and lessons from the past. J Clin Virol 2020. 127: 104362.
[9]
Hanson LA, Söderström T. Human milk: defense against infection. Prog Clin Biol Res 1981; 61: 147-59.
[PMID: 6798576]
[10]
Paramasivam K, Michie C, Opara E, Jewell AP. Human breast milk immunology: a review. Int J Fertil Womens Med 2006; 51(5): 208-17.
[PMID: 17269587]
[11]
Xanthou M, Bines J, Walker WA. Human milk and intestinal host defense in newborns: an update. Adv Pediatr 1995; 42: 171-208.
[PMID: 8540428]
[12]
Singh R, Mal G, Kumar D, Patil NV, Pathak KML. Camel milk: an important natural adjuvant. Agric Res 2017; 6(4): 327-40.
[http://dx.doi.org/10.1007/s40003-017-0284-4]
[13]
Al haj OA and Al Kanhal HA. Compositional, technological and nutritional aspects of dromedary camel milk. Int Dairy J 2010; 20: 811-21.
[14]
Abrhaley A, Leta S. Medicinal value of camel milk and meat. J Appl Anim Res 2018; 46: 552-8.
[http://dx.doi.org/10.1080/09712119.2017.1357562]
[15]
Yang B, Chuang H, Chen RF. Protection from viral infections by human milk oligosaccharides: direct blockade and indirect modulation of intestinal ecology and immune reactions. Open Glycosci 2012; 5: 19-25.
[http://dx.doi.org/10.2174/1875398101205010019]
[16]
Etzold S, Bode L. Glycan-dependent viral infection in infants and the role of human milk oligosaccharides. Curr Opin Virol 2014; 7: 101-7.
[http://dx.doi.org/10.1016/j.coviro.2014.06.005] [PMID: 25047751]
[17]
Morrow AL, Ruiz-Palacios GM, Jiang X, Newburg DS. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. J Nutr 2005; 135(5): 1304-7.
[http://dx.doi.org/10.1093/jn/135.5.1304] [PMID: 15867329]
[18]
Ramani S, Stewart CJ, Laucirica DR, et al. Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. Nat Commun 2018; 9(1): 5010.
[http://dx.doi.org/10.1038/s41467-018-07476-4] [PMID: 30479342]
[19]
Weichert S, Koromyslova A, Singh BK, et al. Structural basis for norovirus inhibition by human milk oligosaccharides. J Virol 2016; 90(9): 4843-8.
[http://dx.doi.org/10.1128/JVI.03223-15] [PMID: 26889023]
[20]
Albrecht S, Lane JA, Mariño K, et al. A comparative study of free oligosaccharides in the milk of domestic animals. Br J Nutr 2014; 111(7): 1313-28.
[http://dx.doi.org/10.1017/S0007114513003772] [PMID: 24635885]
[21]
Ruhaak LR, Lebrilla CB. Analysis and role of oligosaccharides in milk. BMB Rep 2012; 45(8): 442-51.
[http://dx.doi.org/10.5483/BMBRep.2012.45.8.161] [PMID: 22917028]
[22]
Fukuda K, Yamamoto A, Ganzorig K, et al. Chemical characterization of the oligosaccharides in Bactrian camel (Camelus bactrianus) milk and colostrum. J Dairy Sci 2010; 93(12): 5572-87.
[http://dx.doi.org/10.3168/jds.2010-3151] [PMID: 21094729]
[23]
Agrawal RP, Jain S, Shah S, Chopra A, Agarwal V. Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Eur J Clin Nutr 2011; 65(9): 1048-52.
[http://dx.doi.org/10.1038/ejcn.2011.98] [PMID: 21629270]
[24]
El fakharany EM, Abd El baky N, Linjawi MH, et al. Influence of camel milk on the hepatitis C virus burden of infected patients. Exp Ther Med 2017; 13: 1313-20.
[25]
Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from milk: nutraceutical and pharmacological properties. Pharmaceuticals (Basel) 2016; 9(4): E61.
[http://dx.doi.org/10.3390/ph9040061] [PMID: 27690059]
[26]
El-Fakharany EM, Sánchez L, Al-Mehdar HA, Redwan EM. Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study. Virol J 2013; 10: 199.
[http://dx.doi.org/10.1186/1743-422X-10-199] [PMID: 23782993]
[27]
el Agamy EI, Ruppanner R, Ismail A, Champagne CP, Assaf R. Antibacterial and antiviral activity of camel milk protective proteins. J Dairy Res 1992; 59(2): 169-75.
[http://dx.doi.org/10.1017/S0022029900030417] [PMID: 1319434]
[28]
Carter A. Mitchell, Koreen Ramessar, and Barry R. O’Keefe. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res 2017; 142: 37-54.
[http://dx.doi.org/10.1016/j.antiviral.2017.03.007]
[29]
Kumakia Y, Wanderseea MK, Smitha AJ. et al. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Res 2011; 90: 22-32.
[30]
Barton C, Kouokam JC, Lasnik AB, et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother 2014; 58(1): 120-7.
[http://dx.doi.org/10.1128/AAC.01407-13] [PMID: 24145548]
[31]
Millet JK, Séron K, Labitt RN, et al. Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. Antiviral Res 2016; 133: 1-8.
[http://dx.doi.org/10.1016/j.antiviral.2016.07.011] [PMID: 27424494]
[32]
Lee C. Griffithsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application. Mar Drugs 2019; 17(10): 567.
[http://dx.doi.org/10.3390/md17100567] [PMID: 31590428]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy